Corcept Therapeutics Incorporated (CORT)

NASDAQ: CORT · USD

$86.4

-1.23 (-1.4%)· Recorded snapshot

Market cap	9.3B
Revenue (ttm)	830.8M
Net income (ttm)	54.3M
EPS (ttm)	$0.45
Shares out	108.1M
P/E (trailing)	190.4x
P/E (forward)	22.5x
Volume	849,324
Beta	0.40

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 830.8M
Net income (ttm): 54.3M
EPS (ttm): $0.45
P/E (trailing): 190.4x
P/E (forward): 22.5x
Market cap: 9.3B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	ถือ

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/E22.5

P25 n/aP50 n/aP75 n/a

Trailing P/E190.4

P25 n/aP50 n/aP75 n/a

ROE8.2

P25 n/aP50 n/aP75 n/a

ROIC1.8

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All CORT indicators

Market & fundamental data

Available fields

266

Groups with data

Currency

USD

Showing 266 of 266 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001088856
Company name	Corcept Therapeutics Incorporated
Country	United States
Country code	US
CUSIP number	218352102
Earnings date	2026-11-03
Earnings time	amc
Employees	730
Employees change	230
Employees growth	46%
Enterprise value	$8.8B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1998
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US2183521028
Last 10-K release date	2026-02-24
Last earnings date	2026-07-29
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$9.3B
Market cap category	Mid-Cap
Next earnings date	2026-11-03
Options	Yes
Price	$86.36
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	CORT
U.S. state	California
Website	https://www.corcept.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Adjusted P/E ratio	205.62x
Average P/E ratio (10Y)	41.05x
Average P/E ratio (3Y)	59.89x
Average P/E ratio (5Y)	44.82x
Earnings yield	0.53%
EV/Earnings	164.27x
EV/EBIT	1,391.84x
EV/EBITDA	1,102.76x
EV/FCF	83.38x
EV/Sales	10.73x
FCF / EV yield	1.2%
FCF yield	1.13%
Forward EV/Sales	5.97x
Forward P/E	22.49x
Forward P/S	6.33x
Graham number	8.17023
Graham upside	-90.65%
Lynch fair value	$2.27
Lynch upside	-97.41%
P/(FCF - SBC) ratio	873.78x
P/(OCF - SBC) ratio	695.16x
P/B ratio	13.39x
P/E ratio	190.37x
P/FCF ratio	88.38x
P/OCF ratio	86.14x
P/S ratio	11.37x
Price / tangible book value	13.39x
Price/EBITDA ratio	1,168.97x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	0.77%
EBITDA margin	0.97%
FCF margin	12.87%
Gross margin	98.3%
Operating margin	0.77%
Pretax margin	3.17%
Profit margin	6.64%
Profit per employee	$74,342
Profitable quarters	1
Profitable years	10
Revenue per employee	$1.1M
ROA	0.47%
ROA (5Y)	11.16%
ROCE	0.87%
ROE	8.23%
ROE (5Y)	21.6%
ROIC	1.79%
ROIC (5Y)	67.7%
SBC / revenue	11.57%
Tax / revenue	-3.47%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth	-59.3%
EPS growth (Q)	24.14%
EPS growth 10Y	47.69%
EPS growth 3Y	-17.6%
EPS growth 5Y	-9.84%
EPS growth quarters	1
EPS growth years	0
FCF growth	-40.76%
FCF growth (Q)	-29.89%
FCF growth 3Y	-7.43%
FCF growth 5Y	-4.4%
Gross profit growth	16.03%
Gross profit growth (Q)	31.98%
Gross profit growth 3Y	24.58%
Gross profit growth 5Y	19.3%
Net income growth	-58.71%
Net income growth (Q)	22.3%
Net income growth 3Y	-16.81%
Net income growth 5Y	-11.08%
Net income growth quarters	1
Net income growth years	0
OCF growth	-39.86%
OCF growth (Q)	-24.28%
OCF growth 10Y	27.15%
OCF growth 3Y	-6.75%
OCF growth 5Y	-4.1%
Operating income growth	-93.69%
Operating income growth (Q)	54.83%
Operating income growth 3Y	-59.84%
Operating income growth 5Y	-43.04%
Revenue growth	16.02%
Revenue growth (Q)	31.74%
Revenue growth (QoQ)	55.33%
Revenue growth 10Y	29.22%
Revenue growth 3Y	24.73%
Revenue growth 5Y	19.35%
Revenue growth quarters	21
Revenue growth years	13

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-2.8M
Depreciation and amortization	$1.7M
EBIT	$6.4M
EBITDA	$8.1M
EPS	$0.45
FCF per share	$0.99
Financing cash flow	$-78.9M
Free cash flow	$106.9M
Free cash flow minus SBC	$10.8M
Gross profit	$816.7M
Income taxes	$-28.8M
Investing cash flow	$-21.9M
Net cash flow	$8.3M
Net income	$54.3M
Operating cash flow minus SBC	$13.6M
Operating income	$6.4M
Revenue	$830.8M
Stock-based compensation	$96.1M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	24.08
Book value per share	$6.54
Debt / EBITDA	0.86
Debt / equity	0.01
Debt / FCF	0.09
Long-term assets	$449M
Long-term liabilities	$29.1M
Net cash (debt)	$535.2M
Net cash / market cap	5.66%
Net cash growth	5.28%
Net debt / EBITDA	-66.21
Net debt / equity	-0.76
Net debt / FCF	-5.01
Piotroski F-Score	6
Property, plant and equipment	$12M
Shareholders' equity	$705.8M
Tangible book value	$705.8M
Tangible book value per share	$6.54
Total assets	$888.7M
Total cash	$308.2M
Total debt	$9.4M
Total liabilities	$182.9M
WACC	6.45%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.98
Current assets	$439.7M
Current liabilities	$153.8M
Current ratio	2.86
Inventory turnover	1.11
Net working capital	$-20.4M
Quick ratio	2.5
Working capital	$285.9M
Working capital turnover	2.84

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	0.22%
Dividend yield	0%
Shareholder yield	0.22%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	1,152.17%
10Y return CAGR	28.76%
10Y total return	1,152.17%
150-day SMA	$86.61
15Y price change	2,382.81%
15Y return CAGR	23.88%
15Y total return	2,382.81%
1D price change	-1.4%
1M price change	-25.37%
1M total return	-25.37%
1W price change	-25.59%
1W total return	-25.59%
1Y price change	19.42%
1Y return CAGR	19.43%
1Y total return	19.42%
20-day SMA	$110.47
200-day SMA	$74.30
20Y price change	10,597.53%
20Y return CAGR	26.32%
20Y total return	10,597.53%
3M price change	-4.91%
3M total return	-4.91%
3Y price change	217.87%
3Y return CAGR	47.02%
3Y total return	217.87%
50-day SMA	$113.44
50-day SMA vs 200-day SMA	50over200
52-week high	$126.38
52-week high date	2026-08-25
52-week low	$28.66
52-week low date	2026-02-19
5Y price change	392.61%
5Y return CAGR	37.57%
5Y total return	392.61%
6M price change	87.47%
6M total return	87.47%
All-time high	$126.38
All-time high date	2026-08-25
All-time low	$0.68
All-time low date	2006-10-12
Average true range (ATR)	$5.90
Average volume	871.7K
Beta (1Y)	1.11
Beta (2Y)	0.5
Beta (5Y)	0.4
Change from 52-week high	-31.67%
Change from 52-week low	201.33%
Change from all-time high	-31.44%
Change from all-time low	12,642.65%
Change from open	-0.51%
Day's gap	-0.9%
Dollar volume	$73.3M
High price	$88.46
Low price	$86.17
Monthly RSI	55.59
Open price	$86.80
Position in 52-week range	8.3%
Premarket change	0.47%
Premarket close	$87.59
Premarket price	$88.00
Previous close	$87.59
Price vs 150-day SMA	0.05%
Price vs 20-day SMA	-21.57%
Price vs 200-day SMA	16.62%
Price vs 50-day SMA	-23.62%
Relative volume	0.97
RSI	26.21
Sharpe ratio	0.66
Sharpe ratio (3Y)	0.77
Sharpe ratio (5Y)	0.68
Sortino ratio	0.91
Sortino ratio (3Y)	1.49
Sortino ratio (5Y)	1.28
Volume	849.3K
Weekly RSI	45.79
YTD price change	148.99%
YTD total return	148.99%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	96.5M
Float percentage	89.26%
Shares change (QoQ)	13.36%
Shares change (YoY)	-0.22%
Shares held by insiders	10.67%
Shares held by institutions	76.79%
Shares outstanding	108.1M
Short % of float	8.9%
Short % of shares	7.95%
Short ratio	5.1 days

Deeper analysis on CORT

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this CORT report

Is a complete CORT research report available?

No complete published report is available for Corcept Therapeutics Incorporated (CORT) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Corcept Therapeutics Incorporated (CORT)

Price

Financial snapshot

Fair-value bridge

Latest news · CORT

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All CORT indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on CORT

Frequently asked questions